Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.

Boof, Marie-Laure; Géhin, Martine; Voors-Pette, Christine; Hsin, Chih-Hsuan; Sippel, Virginie; Strasser, Daniel S; Dingemanse, Jasper

Boof, Marie-Laure; Géhin, Martine; Voors-Pette, Christine; Hsin, Chih-Hsuan; Sippel, Virginie; Strasser, Daniel S; Dingemanse, Jasper.

Afiliación

Boof ML; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Géhin M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Voors-Pette C; QPS Netherlands BV, Groningen, The Netherlands.
Hsin CH; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Sippel V; Department of Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Strasser DS; Department of Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Br J Clin Pharmacol ; 90(2): 588-599, 2024 02.

Article en En | MEDLINE | ID: mdl-37752659

Asunto(s)

Semivida; Adulto; Humanos; Masculino; Femenino; Relación Dosis-Respuesta a Droga; Área Bajo la Curva; Método Doble Ciego; Voluntarios Sanos; Administración Oral

Palabras clave

C-X-C chemokine receptor 3; first-in-human; pharmacodynamics; pharmacokinetics; safety and tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Semivida Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Revista: Br J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google